Compare PRPL & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | INAB |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 11.8M |
| IPO Year | 2015 | 2020 |
| Metric | PRPL | INAB |
|---|---|---|
| Price | $2.27 | $1.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $20.63 | $7.00 |
| AVG Volume (30 Days) | 44.1K | ★ 45.9K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $468,725,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $0.88 |
| 52 Week High | $10.00 | $2.73 |
| Indicator | PRPL | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 43.78 |
| Support Level | $0.36 | $0.92 |
| Resistance Level | $10.00 | $1.22 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 58.49 | 10.77 |
Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.